Louisiana Attorney General Liz Murrill’s lawsuit against the Food and Drug Administration (FDA), which attempts to restrict access to mifepristone—one of two drugs commonly used in U.S. medication abortions—is heating up.

The case, filed in 2025, centers around a Biden-era rule that removed a requirement for abortion patients to receive mifepristone from a provider in-person and allowed certified retail pharmacies to dispense the drug directly to patients. The requirement was temporarily lifted during the COVID-19 pandemic and was officially codified in 2023, citing a scientific review by agency staff. This was just months after the Supreme Court’s Dobbs v. Jackson Women’s Health Organization decision, which stripped federal abortion protections and led many states to impose abortion bans, increasing the use of telehealth abortion care.

In her complaint, Murrill argued that the FDA’s rule flies in the face of the state’s near-total abortion ban, since providers in other states can mail abortion pills to patients in Louisiana. Missouri, Idaho, Texas, Kansas, and Florida have also sued over the rule.

The case, Louisiana v. U.S. Food and Drug Administration, has the potential to completely alter the state of telehealth medication abortion care, which accounts for nearly 27 percent of all........

© Rewire.News